Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer.
Feng Jiang,Qi Qiu,Abha Khanna,Nevins W. Todd,Janaki Deepak,Lingxiao Xing,Huijun Wang,Zhenqiu Liu,Yun Su,Sanford A. Stass,Ruth L. Katz +10 more
Reads0
Chats0
TLDR
Immunohistochemical analysis of 303 clinical specimens from three independent cohorts of lung cancer patients and controls show that expression of ALDH1 is positively correlated with the stage and grade of lung tumors and related to a poor prognosis for the patients with early-stage lung cancer.Abstract:
Tumor contains small population of cancer stem cells (CSC) that are responsible for its maintenance and relapse. Analysis of these CSCs may lead to effective prognostic and therapeutic strategies for the treatment of cancer patients. We report here the identification of CSCs from human lung cancer cells using Aldefluor assay followed by fluorescence-activated cell sorting analysis. Isolated cancer cells with relatively high aldehyde dehydrogenase 1 (ALDH1) activity display in vitro features of CSCs, including capacities for proliferation, self-renewal, and differentiation, resistance to chemotherapy, and expressing CSC surface marker CD133. In vivo experiments show that the ALDH1-positive cells could generate tumors that recapitulate the heterogeneity of the parental cancer cells. Immunohistochemical analysis of 303 clinical specimens from three independent cohorts of lung cancer patients and controls show that expression of ALDH1 is positively correlated with the stage and grade of lung tumors and related to a poor prognosis for the patients with early-stage lung cancer. ALDH1 is therefore a lung tumor stem cell-associated marker. These findings offer an important new tool for the study of lung CSCs and provide a potential prognostic factor and therapeutic target for treatment of the patients with lung cancer. (Mol Cancer Res 2009;7(3):330–8)read more
Citations
More filters
Journal ArticleDOI
Non-small-cell lung cancers: a heterogeneous set of diseases
TL;DR: An impressive list of potential therapeutic targets was unveiled, drastically altering the clinical evaluation and treatment of patients for non-small-cell lung cancers, including immunotherapy.
Journal ArticleDOI
Tackling the cancer stem cells — what challenges do they pose?
TL;DR: The signalling pathways that create cancer stem cells, cell-intrinsic mechanisms that could be exploited for selective elimination or induction of their differentiation, and the role of the tumour microenvironment in sustaining them are discussed.
Journal ArticleDOI
Targeting cancer stem cell pathways for cancer therapy
Liqun Yang,Pengfei Shi,Gaichao Zhao,Jie Xu,Wen Peng,Jiayi Zhang,Guanghui Zhang,Xiaowen Wang,Zhen Dong,Fei Chen,Hongjuan Cui +10 more
TL;DR: Molecules, vaccines, antibodies, and CAR-T (chimeric antigen receptor T cell) cells have been developed to specifically target CSCs, and some of these factors are already undergoing clinical trials.
Journal ArticleDOI
Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment.
Lan Thi Hanh Phi,Ita Novita Sari,Ying-Gui Yang,Sanghyun Lee,Nayoung Jun,Kwang Seock Kim,Yun Kyung Lee,Hyog Young Kwon +7 more
TL;DR: This review highlights the key features and mechanisms that regulate CSC function in drug resistance as well as recent breakthroughs of therapeutic approaches for targeting CSCs and provides better therapeutic rationales to accompany novel anticancer therapeutics.
Journal ArticleDOI
Erratum: Non-small-cell lung cancers: a heterogeneous set of diseases
TL;DR: ADCs can be modelled by KrasG12D expression (long latency), KrasD expression and Trp53-null, and epidermal growth factor receptor (EGFR)T790M/L858R, among other genetic models, and they are thought to arise from more distal airway cells.
References
More filters
Book ChapterDOI
Class 1 and Class 3 Aldehyde Dehydrogenase Levels in the Human Tumor Cell Lines Currently Used by the National Cancer Institute to Screen for Potentially Useful Antitumor Agents
TL;DR: The results of these tests, viz., GI50, TGI and LC50 values (the concentrations of an agent required to effect 50% growth inhibition, total growth inhibition and 50% cell-kill, respectively) have been, and are being, stored in an electronic database.
Journal ArticleDOI
Comparison of molecular abnormalities in bronchial brushings and tumor touch preparations
Güliz A. Barkan,Nancy P. Caraway,Feng Jiang,Tanweer M. Zaidi,B S Ricardo Fernandez,Ara Vaporcyin,Rodolfo Morice,B.S. Xian Zhou M.S.,Benjamin N. Bekele,Ruth L. Katz +9 more
TL;DR: A pilot study was performed to evaluate the use of DNA fluorescence in situ hybridization (FISH) probes to ascertain whether these biomarkers can predict nonsmall cell lung carcinoma (NSCLC).